Healthcare - Medical - Devices - NASDAQ - US
$ 0.0662
-10.5 %
$ 1.78 M
Market Cap
0.0
P/E
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc.[ Read More ]
The intrinsic value of one BJDX stock under the base case scenario is HIDDEN Compared to the current market price of 0.0662 USD, Bluejay Diagnostics, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart BJDX
FINANCIALS
0
REVENUE
-10.3 M
OPERATING INCOME
-9.95 M
NET INCOME
-8.31 M
OPERATING CASH FLOW
-704 K
INVESTING CASH FLOW
1.11 M
FINANCING CASH FLOW
0
REVENUE
-1.36 M
OPERATING INCOME
-1.48 M
NET INCOME
-1.93 M
OPERATING CASH FLOW
-227
INVESTING CASH FLOW
-371 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Bluejay Diagnostics, Inc.
| Current Assets | 3.22 M |
| Cash & Short-Term Investments | 2.21 M |
| Receivables | 0 |
| Other Current Assets | 1.01 M |
| Non-Current Assets | 1.65 M |
| Long-Term Investments | 0 |
| PP&E | 1.62 M |
| Other Non-Current Assets | 28.7 K |
| Current Liabilities | 1.77 M |
| Accounts Payable | 491 K |
| Short-Term Debt | 163 K |
| Other Current Liabilities | 1.12 M |
| Non-Current Liabilities | 202 K |
| Long-Term Debt | 190 K |
| Other Non-Current Liabilities | 12.3 K |
EFFICIENCY
Earnings Waterfall
Bluejay Diagnostics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 781 K |
| Gross Profit | -781 K |
| Operating Expenses | 10.3 M |
| Operating Income | -10.3 M |
| Other Expenses | -357 K |
| Net Income | -9.95 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-343.85%
ROE
-204.45%
ROA
-356.19%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bluejay Diagnostics, Inc.
| Net Income | -9.95 M |
| Depreciation & Amortization | 781 K |
| Capital Expenditures | -704 K |
| Stock-Based Compensation | 189 K |
| Change in Working Capital | 667 K |
| Others | 906 K |
| Free Cash Flow | -9.02 M |
Wall Street Analysts Price Targets
Bluejay Diagnostics, Inc.
BJDX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Bluejay Diagnostics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
3.17 K USD 2
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
11 months ago
Dec 13, 2023
|
Bought 1.54 K USD
|
Dey Svetlana
Director |
+ 500
|
3.07 USD |
|
11 months ago
Dec 13, 2023
|
Bought 1.64 K USD
|
Dey Indranil
President and CEO |
+ 500
|
3.27 USD |
|
1 year ago
Mar 24, 2023
|
Bought 4.4 K USD
|
Dey Svetlana
Director |
+ 10000
|
0.44 USD |
|
1 year ago
Mar 28, 2023
|
Bought 880 USD
|
Dey Indranil
President and CEO |
+ 2000
|
0.44 USD |
|
1 year ago
Mar 27, 2023
|
Bought 3.52 K USD
|
Dey Indranil
President and CEO |
+ 8000
|
0.44 USD |
|
2 years ago
Aug 26, 2022
|
Bought 20.6 K USD
|
Fisher Kenneth R
director: Chief Financial Officer |
+ 20000
|
1.03 USD |
|
2 years ago
Apr 25, 2022
|
Bought 19.8 K USD
|
Fisher Kenneth R
Chief Financial Officer |
+ 20000
|
0.99 USD |
|
2 years ago
Mar 17, 2022
|
Bought 2.9 K USD
|
Kinder Gordon Winston
Chief Financial Officer |
+ 2500
|
1.159 USD |
|
2 years ago
Mar 17, 2022
|
Bought 11.8 K USD
|
Dey Svetlana
director: |
+ 10000
|
1.183 USD |
|
2 years ago
Mar 17, 2022
|
Bought 47.1 K USD
|
Wurth Douglas Clark
director: |
+ 40000
|
1.178 USD |
|
2 years ago
Mar 16, 2022
|
Bought 65.4 K USD
|
Wurth Douglas Clark
director: |
+ 60000
|
1.09 USD |
|
2 years ago
Mar 14, 2022
|
Bought 5.1 K USD
|
Kinder Gordon Winston
Chief Financial Officer |
+ 5000
|
1.02 USD |
7. News
Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company's existing trading symbol, “BJDX.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633509.
globenewswire.com
- 3 days ago
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
globenewswire.com
- 4 months ago
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).
globenewswire.com
- 4 months ago
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2,692,308 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants have an exercise price of $1.30 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance.
globenewswire.com
- 10 months ago
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants will have an exercise price of $1.30 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The closing of the offering is expected to occur on or about January 2, 2024, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 10 months ago
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.
globenewswire.com
- 10 months ago
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2023.
globenewswire.com
- 1 year ago
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
ACTON, Mass., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into a definitive agreement for the purchase and sale of 216,000 shares of the Company's common stock at a purchase price of $7.365 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 216,000 shares of its common stock. The warrants will have an exercise price of $7.24 per share and will be immediately exercisable upon issuance for a period of five years. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 28, 2023, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 1 year ago
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
ACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced financial results for the six months ended June 30, 2023.
globenewswire.com
- 1 year ago
Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass., July 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”), with a corresponding reduction in the number of authorized outstanding number of shares of common stock from 100,000,000 to 7,500,000. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on July 24, 2023, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on July 24, 2023 under the Company's existing trading symbol, “BJDX.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633301.
globenewswire.com
- 1 year ago
Why Is Bluejay Diagnostics (BJDX) Stock Up 17% Today?
Bluejay Diagnostics (NASDAQ: BJDX ) stock is rising higher on Friday despite a lack of news from the medical diagnostic company. There have been no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rallying this morning.
investorplace.com
- 1 year ago
Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
benzinga.com
- 2 years ago
8. Profile Summary
Bluejay Diagnostics, Inc. BJDX
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 1.78 M
Dividend Yield
0.00%
Description
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Contact
360 Massachusetts Avenue, Acton, MA, 01720
https://www.bluejaydx.com
IPO Date
Nov. 10, 2021
Employees
10
Officers
Mark W. Feinberg
Chief Medical Advisor
Mr. Indranil Dey
Principal Financial, Accounting & Executive Officer, President, Chief Executive Officer and Director
Mr. Kevin Vance
Chief Commercial Officer
Dr. Jason Cook
Chief Technology Officer
Mr. Les DeLuca
Vice President of Operations
Dr. Mark W. Feinberg M.D.
Chief Medical Advisor